Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
- PMID: 15166541
- DOI: 10.1097/00002030-200405210-00019
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
Abstract
The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from The Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV.
Similar articles
-
Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5.Int J Pharm. 2024 Sep 5;662:124480. doi: 10.1016/j.ijpharm.2024.124480. Epub 2024 Jul 20. Int J Pharm. 2024. PMID: 39038719
-
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.J Virol. 2004 Dec;78(23):13207-15. doi: 10.1128/JVI.78.23.13207-13215.2004. J Virol. 2004. PMID: 15542673 Free PMC article.
-
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.J Clin Microbiol. 2006 Oct;44(10):3781-3. doi: 10.1128/JCM.01249-06. J Clin Microbiol. 2006. PMID: 17021110 Free PMC article.
-
Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis.Lancet Infect Dis. 2015 Jul;15(7):819-24. doi: 10.1016/S1473-3099(15)00006-7. Epub 2015 May 5. Lancet Infect Dis. 2015. PMID: 25957078 Review.
-
Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV).Semin Cancer Biol. 1999 Jun;9(3):175-85. doi: 10.1006/scbi.1998.0089. Semin Cancer Biol. 1999. PMID: 10343069 Review.
Cited by
-
Human immunodeficiency virus vaccine trials.Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a007351. doi: 10.1101/cshperspect.a007351. Cold Spring Harb Perspect Med. 2012. PMID: 23209178 Free PMC article. Review.
-
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.PLoS One. 2012;7(8):e41936. doi: 10.1371/journal.pone.0041936. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22870265 Free PMC article. Clinical Trial.
-
Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters.PLoS One. 2012;7(1):e30302. doi: 10.1371/journal.pone.0030302. Epub 2012 Jan 19. PLoS One. 2012. PMID: 22276174 Free PMC article.
-
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.J Virol. 2007 May;81(9):4654-63. doi: 10.1128/JVI.02696-06. Epub 2007 Feb 28. J Virol. 2007. PMID: 17329340 Free PMC article.
-
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".J Virol. 2008 Apr;82(7):3166-80. doi: 10.1128/JVI.01634-07. Epub 2007 Nov 7. J Virol. 2008. PMID: 17989174 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical